Table 3 Reverse transcriptase inhibitors associated drug resistance mutations (DRM) in patients failing therapy at month 6 and/or 12 by the type of first-line regimen
DRM at VL > 1000 copies/ml | Tenofovir | Zidovudine | p-value |
|---|---|---|---|
Month 6 | |||
  > 1000 copies/ml, readable sequence | 28/34; 82.4% | 15/19; 78.9% | 0.755 |
 NRTI | 17/28; 60.7% | 6/15; 40.0% | 0.195 |
 TAM | 6/28; 21.4% | 4/15; 26.7% | 0.695 |
 K65R | 10/28; 35.7% | 0/15; 0.0% | 0.008 |
 M184I/V | 9/28; 32.1% | 4/15; 26.7% | 0.713 |
 Others (TDF: A62V, K70E, V75I, Y115F, F116Y; ZDV: L74 V) | 7/28; 25.0% | 1/15; 6.7% | 0.142 |
 NNRTI | 21/28; 75.0% | 11/15; 73.3% | 0.903 |
 NRTI + NNRTI | 17/28; 60.7% | 5/15; 33.3% | 0.087 |
 None | 7/28; 25.0% | 3/15; 20.0% | 0.711 |
Month 12 | |||
  > 1000 copies/ml, readable sequence | 16/17; 94.1% | 10/12; 83.3% | 0.347 |
 NRTI | 12/16; 75.0% | 3/10; 30.0% | 0.024 |
 TAM | 5/16; 31.3% | 2/10; 20.0% | 0.528 |
 K65R | 8/16; 50.0% | 0/10; 0.0% | 0.007 |
 M184I/V | 7/16; 43.8% | 1/10; 10.0% | 0.069 |
 Others (TDF: A62V, K70E, V75I, Y115F) | 4/16; 25.0% | 0/10; 0.0% | 0.086 |
 NNRTI | 13/16; 81.3% | 4/10; 40.0% | 0.031 |
 NRTI + NNRTI | 12/16; 75.0% | 2/10; 20.0% | 0.006 |
 None | 3/16; 18.8% | 5/10; 50.0% | 0.094 |